You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 102 No. 7, July 1984 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLE
 This Article
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Hematoporphyrin derivative photoradiation therapy in managing nevoid basal-cell carcinoma syndrome. A preliminary report

D. T. Tse, R. C. Kersten and R. L. Anderson

Hematoporphyrin derivative (HpD) is a photodynamically active dye that is preferentially retained by malignant tissues and initiates a cytotoxic reaction when exposed to red light. Normal tissues adjacent to a tumor retain HpD to a lesser degree and are thus spared damage from the light-induced reaction. We describe the treatment of 40 basal-cell carcinomas in three patients with nevoid basal-cell carcinoma syndrome. All treated lesions showed disappearance of clinically apparent tumor within four to six weeks, and there was no damage to surrounding skin. Thirty-three lesions (82.5%) showed complete response on biopsy findings, while seven showed residual tumor cells. The recurrence rate was 10.8%, with the follow-up ranging from 12 to 14 months. Tumor response was related to the total light dose delivered and the size and location of the tumor.





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1984 American Medical Association. All Rights Reserved.